Últimas noticias sobre Opthea (NASDAQ:OPT) Bolsa

Opthea

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

Opthea Limited - American Depositary Shares

Opthea Ltd

Opus - United States Dollar

ORIENTAL PET & MINERAL B by Oriental Petroleum & Mineral

Oriental Petroleum & Minerals Corp

OPTIMUS GROUP CO LTD. by OPTIMUS GROUP CO LTD.

Optimus Group Co Ltd

OPTIMI HEALTH CORP by OPTIMI HEALTH CORP.

Optimi Health Corp

OPTEC INTERNATIONAL INC by Optec International, Inc.

Optec International Inc

OPTIMUM INTRACTVE USA NEW by Optimum Interactive USA Ltd.

Optimum Interactive USA Ltd

OptiNose Inc

Ocean Power Technologies, Inc. Common Stock

Ocean Power Technologies Inc

Syntec Optics Holdings, Inc. - Class A Common Stock

Syntec Optics Holdings Inc

Optimize Strategy Index ETF

WIIM

Meta Platforms shares are trading higher after JMP Securities raised its price target on the stock from $660 to $750.

In the current market session, Beacon Roofing Supply Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BECN#NASDAQ">BECN</a>) share price is at $102.70, after a 1.10% increase. Moreover, over the past month, the stock fell by 10.91%, but in the past year, went up by 16.78%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1735837209_0.png" alt="Past Year Chart" />

<h3>Evaluating Beacon Roofing Supply P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Beacon Roofing Supply has a lower P/E than the aggregate P/E of 93.58 of the Trading Companies &amp; Distributors industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1735837209_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

Markets

BECN

P/E Ratio Insights for Beacon Roofing Supply

AAPL

Apple shares are trading lower after reports indicating the company is discounting iPhone 16 prices in China.

Constellation shares are trading higher after the company announced it won $1 billion in combined contracts from the U.S. General Services Administration.

UBS analyst Shaleen Kumar upgrades Wipro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WIT#NYSE">WIT</a>) from Sell to Neutral.

Upgrades

Analyst Ratings

UBS Upgrades Wipro to Neutral

Macro Economic Events

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher, with chip stocks rising to begin 2025.

Nio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) closed 2024 with a bang, delivering a <a href="https://www.benzinga.com//node/42758569">record-breaking 31,138 vehicles</a> in December — a staggering 72.9% year-over-year jump. 
Quarterly deliveries hit an all-time high of 72,689, while annual deliveries climbed to 221,970, marking a 38.7% surge from the previous year.
Yet, Nio stock&#8217;s technicals paint a less rosy picture.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="629" height="492" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02104706/Screenshot-2025-01-02-at-9.16.54-PM.png" alt="" class="wp-image-715488" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02104706/Screenshot-2025-01-02-at-9.16.54-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02104706/Screenshot-2025-01-02-at-9.16.54-PM-300x235.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010225&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Nio stock recently formed a dreaded <a href="https://www.benzinga.com/topic/death-cross">Death Cross</a> — a bearish technical signal where the 50-day moving average dips below the 200-day moving average. Despite posting a 7.57% gain during the early hours of trading on Thursday and a 6.59% increase over the past month, NIO stock&#8217;s overall trend remains bleak.
Trading at $4.62, the stock lags behind its medium- and long-term moving averages, signaling persistent selling pressure.
Read Also: <a href="https://www.benzinga.com//node/42761825">EV Price War Heats Up As Chinese Automakers Extend Subsidies: Details</a>
<h2 class="wp-block-heading">A Tale Of Two Trends</h2>
While delivery numbers suggest growth, technical indicators tell a different story. Nio's Relative Strength Index (RSI) sits at 50.32, signaling mild bearish momentum, and the Moving Average Convergence Divergence (MACD) indicator of a negative 0.1 leans bearish. 
These technical signs raise concerns about whether the stock can sustain its recent upward movement or faces further declines.
<h2 class="wp-block-heading">What's Next?</h2>
Nio&#8217;s ambitious plans, including the launch of its executive ET9 model and the Firefly brand in early 2025, aim to fuel long-term growth. 
However, with Nio stock down 44.3% over the past year, investors are looking for a decisive break above key resistance levels to regain confidence.
The Death Cross may signal caution for now, but with delivery momentum and product innovation on its side, Nio could surprise skeptics. For now, the market awaits confirmation of whether bulls or bears will dominate the road ahead.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com//node/42767647">Chinese Stocks Drop As Manufacturing Growth Slows And Geopolitical Tensions Hit</a></li>
</ul>
Image: Shutterstock

Technicals

Trading Ideas

Nio Death Cross Shadows Record Deliveries: Can Bulls Reclaim The Wheel?

Short seller Hindenburg Research is betting against Carvana Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with the stock up more than 300% over the past year. Despite the bearish report, shares are moving higher on Thursday. Here&#8217;s a look at <a href="https://www.benzinga.com/topic/short-sellers">what you need to know</a>.
What To Know: Hindenburg announced a short position against used car retailer Carvana on Thursday in a <a href="https://hindenburgresearch.com/carvana/">report</a> titled, &#8220;Carvana: A Father-Son Accounting Grift For The Ages.&#8221;
The short seller noted that Carvana shares have soared over the past year on hopes that the worst is behind the company after the car seller battled bankruptcy risks in 2022 and 2023.
&#8220;However, our research, including extensive document review and 49 interviews with industry experts, former Carvana employees, competitors and related parties of the company, undertaken over the course of 4 months, shows Carvana's turnaround is a mirage,&#8221; Hindenburg alleged.
Benzinga has reached out to Carvana for comment on the report.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42766117/tesla-stock-tumbles-on-q4-deliveries-whats-going-on#google_vignette">Tesla Stock Tumbles On Q4 Deliveries: What&#8217;s Going On?</a>
<a href="http://benzinga.com/quote/cvna">Carvana shares</a> fell about 5% when the report was released, but quickly bounced back. The stock was up more than 3% at last check, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Hindenburg claimed its research uncovered &#8220;accounting manipulation and lax underwriting&#8221; that have &#8220;fueled temporary reported income growth.&#8221; The short seller said it also found $800 million in loan sales to a &#8220;suspected undisclosed related party.&#8221;
Hindenburg went on to highlight recent insider selling, suggesting the company&#8217;s share price is inflated. All findings aside, the short seller believes the stock is &#8220;exorbitantly valued,&#8221; trading with a 845% higher sales multiple than competitors CarMax and AutoNation, and a 754% higher forward earnings multiple. Carvana currently has a forward price-to-earnings multiple of approximately 101, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
CVNA Price Action: Carvana shares were up 3.37% at $210.20 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Short Sellers

Short Ideas

Movers

CVNA

Hindenburg Shorts Carvana Stock, Claims Used Car Retailer's Turnaround Is A 'Mirage'

INLF

Trading Halt: Halt status updated at 11:50:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Boeing shares are trading lower. The recent crash of a JejuAir flight and China's new trade controls may be weighing on shares.

Goldman Sachs analyst Gabriela Borges maintains Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Buy and raises the price target from $100 to $114.

Price Target

FTNT

Goldman Sachs Maintains Buy on Fortinet, Raises Price Target to $114

<ul>
<li>TSLA</li>
<li>NVDA</li>
<li>LUNR</li>
<li>AAPL</li>
<li>MSTR</li>
<li>AMD</li>
<li>CVNA</li>
<li>QQQ</li>
<li>RKLB</li>
<li>GOOG</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

GOOG

LUNR

MSTR

NVDA

RKLB

TSLA

Top 10 Trending Stocks On WallStreetBets As Of January 2, 2025 (Via Swaggy Stocks)

Shares of Kopin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOPN#NASDAQ">KOPN</a>) were <a href="https://www.benzinga.com/quote/KOPN">climbing in early trading on Thursday</a>.
The provider of advanced microdisplays for military applications is poised to benefit from the continued growth of defense budgets across the U.S. and NATO countries, according to Canaccord Genuity.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/619bb1b28a6ef800019b5d2d/george-gianarikas">Analyst George Gianarikas</a> initiated coverage of Kopin with a Buy rating and a price target of $2.
The Kopin Thesis: While the defense market contributes around 80% of revenues, the company is exploring new growth avenues in the civilian market, Gianarikas said in the initiation note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Kopin could benefit from the rising interest in augmented reality/virtual reality (AR/VR) technologies, which offers "promising prospects" in consumer electronics and medical applications, he added.
"CEO Michael Murray (started September 2022) continues to improve operations, resulting in a potential turn to profitability in 2025," the analyst wrote. "We further see optionality as the company could look to expand either through targeted acquisitions or as an acquisition target itself," he further stated.
Price Action: Shares of Kopin had risen by 4.41% to $1.42 at the time of publication on Thursday.
Read More: <a href="https://www.benzinga.com/24/12/42535789/quicklogic-is-poised-to-benefit-from-cold-war-20-weaponization-of-outer-space-says-bullish-analyst">QuickLogic Analyst Sees &#8216;Cold War 2.0&#8217; As Growth Catalyst</a>
Image: Shutterstock

Analyst Color

Long Ideas

Initiation

KOPN

Kopin Explores New Growth Avenues Beyond Defense, Poised To Turn Profitable In 2025

Stock Split

IDAI

Trust Stamp To Implement 1-For-15 Reverse Stock Split Effective January 6, 2025

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 10 years by 9.12% on an annualized basis producing an average annual return of 20.37%. Currently, Boston Scientific has a market capitalization of $131.90 billion. 
Buying $1000 In BSX: If an investor had bought $1000 of BSX stock 10 years ago, it would be worth $6,537.96 today based on a price of $89.57 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735836310_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Boston Scientific 10 Years Ago Would Be Worth Today

Jefferies analyst David Katz maintains Sunstone Hotel Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHO#NYSE">SHO</a>) with a Hold and raises the price target from $10 to $12.

Jefferies Maintains Hold on Sunstone Hotel Invts, Raises Price Target to $12

BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) shares are<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> trading higher on Thursday.</a>
The company has announced a rebranding of its division, previously known as &#8216;BlackBerry IoT,&#8217; renaming it &#8216;QNX&#8217; and relaunching the brand to strengthen its presence in the automotive and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/ac42763883/blackberry-unveils-strategic-relaunch-of-qnx-brand-to-reinforce-leadership-in-automotive-and-gene" rel="noreferrer noopener">embedded industries.</a>
The move, which stems from feedback from customers, partners, and employees, marks a milestone in QNX&#8217;s history, emphasizing its role in powering next-generation Software-Defined Vehicles and mission-critical systems.
Acquired by BlackBerry in 2010, QNX has become a prominent player in real-time operating systems. In the last fiscal year, QNX launched the QNX SDP 8.0, a scalable foundation for next-generation automotive and IoT systems, alongside QNX Sound, an audio innovation platform for SDVs, and QNX Everywhere, an initiative designed to spur a more open development environment for QNX technologies.
John J. Giamatteo, CEO of BlackBerry, highlighted that this rebranding is part of the company&#8217;s strategy to increase visibility and leadership in these industries, with a focus on growth and innovation.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42763048/powering-up-charging-tesla-to-deploy-first-v4-superchargers-in-china-by-2025" rel="noreferrer noopener">Tesla To Deploy First V4 Superchargers In China By 2025: Report</a>
QNX technology is already integrated into over 255 million vehicles worldwide, as well as critical systems in healthcare, industrial controls, robotics, and more.
&#8220;BlackBerry is at an inflection point and QNX is well positioned for the next 10 years as the demand for advanced hybrid cloud/edge computing capabilities becomes crucial for driving a software-defined future. The investments we have made over the last three years have set us on a well-defined path to capitalize on these trends,&#8221; said Mattias Eriksson, President, QNX.
To accompany the rebranding, BlackBerry unveiled a refreshed logo, website, and visual identity, which will be showcased at CES 2025 in Las Vegas.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, BB stock has gained over 14% in the past year. Investors can gain exposure to the stock via&nbsp;SPDR S&amp;P Kensho Future Security ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FITE#NYSE">FITE</a>).
Price Action: BB shares are trading higher by 4.23% to $3.94 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/01/42757919/joe-biden-addresses-new-orleans-attack-says-law-enforcement-probing-links-with-cybertruck-explosion-outside-trump-hotel-in-las-vegas" target="_blank" rel="noreferrer noopener">Joe Biden Addresses New Orleans Attack Says Law Enforcement Probing Links With Cybertruck Explosion Outside Trump Hotel In Las Vegas</a></li>
</ul>

Equities

Tech

General

FITE

BlackBerry Rebrands IoT Division As QNX - What's Driving The Change?

Jefferies analyst David Katz maintains Xenia Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XHR#NYSE">XHR</a>) with a Buy and raises the price target from $18 to $20.

Jefferies Maintains Buy on Xenia Hotels & Resorts, Raises Price Target to $20

Jefferies analyst David Katz maintains Park Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PK#NYSE">PK</a>) with a Buy and lowers the price target from $23 to $22.

Jefferies Maintains Buy on Park Hotels & Resorts, Lowers Price Target to $22

Carmell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) disclosed that it has entered into a definitive purchase agreement with PMGC Holdings Inc. (formerly Elevai Labs Inc.) and its subsidiary, Elevai Skincare Inc., for purchase consideration, which includes around $1.1 million in <a href="https://www.benzinga.com/pressreleases/25/01/g42762528/carmell-announces-execution-of-definitive-agreement-to-acquire-elevai-skincare-a-leader-in-physici" target="_blank" rel="noreferrer noopener">Carmell stock at the closing of the acquisition</a>.
Additionally, Carmell will pay around $57,000 in cash for the sale of specified inventory existing as of the closing.
Furthermore, the acquisition includes contingent earnout considerations. This comprises 5% of net sales from Elevai&#8217;s existing products, which will be paid annually over the next five years.
A one-time milestone payment of $500,000 will be made if Elevai&#8217;s hair and scalp products generate $500,000 in net revenue within 24 months of the closing.
Lastly, Carmell will assume Elevai&#8217;s contractual liabilities and trade payables at the time of closing.
Carmell expects to acquire several assets from Elevai as part of the acquisition.
These assets include a product portfolio with trailing twelve-month revenue of approximately $2.5 million, as well as the commercial and product development team.
Additionally, Carmell will acquire finished and work-in-process inventory valued at approximately $1.0 million, along with accounts receivable of about $30,000.
Rajiv Shukla, chairman of Carmell said, &#8220;This acquisition will integrate one of the newest advances in stem cell derived exosome technology into the Carmell platform, further cementing our status as the home of the best bio-aesthetic skincare science, Built by Biology just as Nature intended.&#8221;
As of Sept. 30, 2024, the company had cash and cash equivalents <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318716575&amp;type=PDF&amp;symbol=CTCX&amp;cdn=364b0da5c720a5cb08623287e5aeba2e&amp;companyName=Carmell+Corporation&amp;formType=10-Q&amp;formDescription=General+form+for+quarterly+reports+under+Section+13+or+15%28d%29&amp;dateFiled=2024-11-14" target="_blank" rel="noreferrer noopener">of </a>$25,297.
Last week, the company entered into a securities purchase <a target="_blank" href="https://www.benzinga.com/news/financing/24/12/42673289/why-biotechnology-company-carmell-shares-are-seeing-blue-skies-tuesday" rel="noreferrer noopener">agreement&nbsp;with new and existing investors</a>.
The agreement involves the issuance and sale of 8,065,210 shares of common stock and an equal number of five-year warrants, both priced at $0.23 per share, in a private placement.
Price Action: CTCX shares are up 215.8% at $0.88 premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42764308" target="_blank" rel="noreferrer noopener">D.O.G.E. Zooms 48% Higher Ahead Of Elon Musk-Led Agency Launching In January: &#8216;Ready For The Next Leg Up,&#8217; Millionaire Trader Vows</a></li>
</ul>
Photo: Shutterstock

Health Care

Small Cap

CTCX

Why Biotechnology Company Carmell Shares Are Rocketing On Thursday

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on OPT stock, giving a Buy rating on September 12. Debanjana Chatterj...

Opthea Limited: Strong Buy Rating on Manufacturing Milestones and Positive Financial Outlook

Opthea joins S&P/ASX 300 index

Analyst Debanjana Chatterjee of JonesTrading maintained a Buy rating on Opthea Limited Sponsored ADR (OPT – Research Report), retaining the price t...

Opthea Limited's Sozinibercept: A Promising Therapy for wAMD with Strong Financial Backing

Opthea Limited Sponsored ADR (OPT) has released an update. Opthea Limited Sponsored ADR is making strides in the treatment of neovascular age-relat...

Opthea Advances nAMD Treatment with Sozinibercept

Opthea Limited Sponsored ADR (OPT) has released an update. Opthea Limited, a biopharmaceutical firm focusing on treatments for retinal diseases lik...

Opthea Advances Retinal Disease Treatments

Opthea appoints Tom Reilly as CFO

Opthea Limited: Major Catalyst In Early 2025 For Complementary Eye Disease Candidate

Opthea (OPT) announced the appointment of Kathy Connell to the Board of Directors as a Non-Executive Director. Ms. Connell's appointment was effect...

Opthea appoints Kathy Connell to board of directors

Tracking Baker Brothers Portfolio - Q3 2024 Update

Opthea Limited Sponsored ADR ( ($OPT) ) has issued an update. Opthea Limited announced that its CEO, Frederic Guerard, will present at the 43rd Ann...

Opthea to Present Phase 3 Trial Update at J.P. Morgan Healthcare Conference

ABCL

ACAD

ALGS

ALKS

ARGNF

ARGX

AVTE

BCYC

BEIGF

BGNE

BMEA

CERS

CKDXF

DNLI

EWTX

GLUE

HOOK

IGMS

IMCR

IMTX

INCY

INSM

KALA

KNSA

KYMR

MDGL

NRIX

RARE

REPL

RVMD

RYTM

SGMT

SMMT

STOK

TCRX

TRDA

TSVT

VTVT

Press Releases

Opthea to Participate in the UBS Virtual Ophthalmology Day 2024

Management

Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

Comments

Opthea

Noticias

Últimas noticias sobre Opthea (NASDAQ:OPT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL